Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway

Lin,Jiumao; Zhou,Jianheng; Xu,Wei; Zhong,Xiaoyong; Hong,Zhenfeng; Peng,Jun

doi:10.3892/etm.2013.1008

Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway

Authors:
- Jiumao Lin
- Jianheng Zhou
- Wei Xu
- Xiaoyong Zhong
- Zhenfeng Hong
- Jun Peng
View Affiliations

Affiliations: Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Minhou Shangjie, Fuzhou, Fujian 350122, P.R. China, Department of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Minhou Shangjie, Fuzhou, Fujian 350122, P.R. China, Department of Pharmacology, Fujian University of Traditional Chinese Medicine, Minhou Shangjie, Fuzhou, Fujian 350122, P.R. China, Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Minhou Shangjie, Fuzhou, Fujian 350122, P.R. China
Published online on: March 15, 2013 https://doi.org/10.3892/etm.2013.1008
Pages: 1293-1300

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Benign prostatic hyperplasia (BPH) is a pathological overgrowth of the human prostate. It may cause increased resistance to urine flow through the urethra and occasionally kidney damage, bladder stones and urinary tract infections, and therefore affect the quality of life. Qianliening capsule (QC) is a traditional Chinese formula that has been used clinically in China to treat BPH for a number of years. However, the mechanism of its anti-BPH effect remains largely unknown. We evaluated the therapeutic effect of QC in a rat model of BPH, established by the injection of testosterone following castration, and investigated the underlying molecular mechanism of action. We observed that QC treatment significantly and dose-dependently decreased the prostatic volume (PV) and prostatic index (PI; P<0.05 or P<0.01), and ameliorated the histological damage of the prostate tissue in the BPH rats. In addition, treatment with QC inhibited the phosphorylation of signal transducer and activator of transcription 3 (STAT3), as well as the expression of epidermal growth factor (EGF), epidermal growth factor receptor (EGFR), cyclin D1 and Bcl-2. Our results suggest that suppression of the EGF/STAT3 pathway may be one of the mechanisms by which QC treats BPH.

View Figures

View References

1.	Paolone DR: Benign prostatic hyperplasia. Clin Geriatr Med. 26:223–239. 2010. View Article : Google Scholar
2.	Roehrborn CG: Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 95:87–100. 2011. View Article : Google Scholar : PubMed/NCBI
3.	Gat Y, Gornish M, Heiblum M and Joshua S: Reversal of benign prostate hyperplasia by selective occlusion of impaired venous drainage in the male reproductive system: novel mechanism, new treatment. Androl. 40:273–281. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Xie Q, Wang H, Lin F and Liao Y: Abnormality of growth regulatory factors in benign prostatic hyperplasia. Chin J Urol. 22:520–522. 2001.(In Chinese).
5.	Steiner MS: Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol. 153:1085–1096. 1995. View Article : Google Scholar : PubMed/NCBI
6.	Li Y, Fang Y, Xu Youqi, Li Q, Deng X and Jiang J: Role of the epidermal growth factor receptor in human benign hyperplastic prostate tissue. J Clin Urol. 11:199–201. 1996.(In Chinese).
7.	Jia B, Tang Z, Li WM and Cai WQ: The effects of epidermal growth factor on the expression of Bcl-2, Bax and c-myc in mice prostate cells. Chin J Gerontol. 27:251–252. 2007.(In Chinese).
8.	Lin JM, Hong ZF, Zhou JH, Zhuang QC, Zhao JY and Zhou HT: Expression of growth factor related to angiogenesis on prostatic hyperplasia in rats. J Fujian Univ Tradit Chin Med. 18:63–66. 2008.(In Chinese).
9.	Darnell JE Jr: STATs and gene regulation. Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
10.	Hong ZF: Candidate targets for research on benign prostatic hyperplasia. Zhonghua Nan Ke Xue. 14:771–774. 2008.(In Chinese).
11.	Haura EB, Turkson J and Jove R: Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS and Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
13.	Karni R, Jove R and Levitzki A: Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene. 18:4654–4662. 1999. View Article : Google Scholar
14.	Coqueret O and Gascan H: Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J Biol Chem. 275:18794–18800. 2000. View Article : Google Scholar : PubMed/NCBI
15.	Bienvenu F, Gascan H and Coqueret O: Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism. J Biol Chem. 276:16840–16847. 2001. View Article : Google Scholar : PubMed/NCBI
16.	Roehrborn CG, Nuckolls JG, Wei JT and Steers W; BPH Registry and Patient Survey Steering Committee: The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Inter. 100:813–819. 2007. View Article : Google Scholar
17.	Black L, Naslund MJ, Gilbert TD Jr, Davis EA and Ollendorf DA: An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Amer J Manag Care. 12(4 Suppl): S99–S110. 2006.PubMed/NCBI
18.	MacDonald R and Wilt TJ: Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: A systematic review of efficacy and adverse effects. Urology. 66:780–788. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Roehrborn CG: Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology. 58:953–959. 2001. View Article : Google Scholar
20.	Djavan B and Marberger M: A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 36:1–13. 1999.
21.	Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR and Tenover JS: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 327:1185–1191. 1992. View Article : Google Scholar : PubMed/NCBI
22.	Roehrborn C, Boyle P, Nickel JC, Hoefner K and Andriole G; ARIA3001 ARIA3002 and ARIA3003 Study Investigators: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 60:434–441. 2002. View Article : Google Scholar : PubMed/NCBI
23.	Boyle P, Robertson C, Lowe F and Roehrborn C: Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology. 55:533–539. 2000. View Article : Google Scholar : PubMed/NCBI
24.	Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C and Lau J: Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database of Syst Rev. (2): CD0010432000.PubMed/NCBI
25.	Wilt T, Ishani A, Mac Donald R, Rutks I and Stark G: Pygeum africanum for benign prostatic hyperplasia. Cochrane Database of Syst Rev. (1): CD0010442002.PubMed/NCBI
26.	Zhou J, Lin J, Xu W, Zhong X, Xie J and Hong Z: Effects of Qianliening capsule on the expression of IL-10 and TNF-α in benign prostatic hyperplasia. Chin Arch Tradit Chin Med. 28:2657–2569. 2010.(In Chinese).
27.	Zhou JH, Hong ZF, Lin JM, Zhao JY and Zhou HT: Effect of Qianliening granule on experimental hyperplasia of prostate. J Fujian Univ Tradit Chin Med. 18:45–47. 2008.(In Chinese).
28.	Zhou HT, Lin JM, Zhao JY, Zhou JH and Hong ZF: Inhibition effects of qianliening granule on IL-1β and its mRNA expression in model rats. J Fujian Univ Tradit Chin Med. 20:21–24. 2010.
29.	Zhou J, Lin J, Xu W, Zhong X, Zheng Y, Hong Z and Peng J: Qianliening capsule treats benign prostatic hyperplasia through regulating the expression of sex hormones, estrogen receptor and androgen receptor. Afr J Pharm Pharmacol. 6:173–180. 2012. View Article : Google Scholar
30.	Zhong X, Lin J, Zhou J, Xu W, Hong Z and Peng J: Qianliening capsule treats benign prostatic hyperplasia (BPH) by down-regulating the expression of PCNA, CyclinD1 and CDK4. Afr J Biotechnol. 11:7731–7737. 2012.
31.	National Advisory Committee for Laboratory Animal Research. Guidelines on the Care and Use of Animals for Scientific Purposes. 2004
32.	Zheng HY, Xu W, Lin JM, Li H, Zhou JH and Hong ZF: Toxicological studies on qianliening capsule. J Zhejiang Univ Tradit Chin Med. 35:63–65. 2011.(In Chinese).
33.	Ilio KY, Sensibar JA and Lee C: Effect of TGF-beta 1, TGF-alpha, and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture. J Androl. 16:482–490. 1995.PubMed/NCBI
34.	Peng J, Chen Y, Lin J, Zhuang Q, Xu W, Hong Z and Sferra TJ: Patrinia scabiosaefolia extract suppresses proliferation and promotes apoptosis by inhibiting the STAT3 pathway in human multiple myeloma cells. Mol Med Report. 4:313–318. 2011.
35.	Ball S, Li C, Li PK and Lin J: The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One. 6:e188202011. View Article : Google Scholar : PubMed/NCBI
36.	Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 62:3351–3355. 2002.PubMed/NCBI